Low-Dose Ketamine for Eating Disorders: Anorexia, Bulimia, and Binge Eating

Low dose ketamine is not an established treatment for anorexia nervosa, bulimia nervosa, or binge-eating disorder. Research is early, and ketamine should not replace specialized eating disorder care, nutritional rehabilitation, or psychotherapy. For a medically stable person with an eating disorder and difficult-to-treat depression, a qualified clinician may consider whether ketamine is appropriate as part of a closely coordinated treatment plan.

Eating disorders can be medically serious and may require urgent assessment. The National Institute of Mental Health reports that an estimated 0.8% of U.S. adults had binge-eating disorder in the past year in 2021. That figure does not establish that ketamine treats binge eating, but it shows why better treatment research matters.

What research can and cannot say

Ketamine is an anesthetic medicine that affects glutamate signaling. Its rapid antidepressant effects have been studied more extensively in treatment-resistant depression than in eating disorders. The U.S. Food and Drug Administration has approved esketamine nasal spray for certain adults with treatment-resistant depression and depressive symptoms in major depressive disorder with acute suicidal ideation or behavior, under specific conditions. That approval does not include eating disorders. See the FDA's Spravato prescribing information for the approved indications and safety warnings.

Small studies, case reports, and theoretical models have explored whether ketamine could affect depression, cognitive rigidity, rumination, or compulsive behavior in people with eating disorders. Those findings are not enough to show that ketamine improves weight restoration, reduces binge-purge behavior over time, or prevents relapse. A promising change in mood or flexibility is different from proven treatment of the eating disorder itself.

Glutamate is a major signaling chemical in the brain. Researchers are investigating glutamate-related differences in eating disorders, but these findings do not yet provide a dosing rule or a way to predict who will benefit from ketamine. Read more about the proposed biology in neuroplasticity and ketamine and default mode network studies.

Why eating disorder care changes the safety discussion

Eating disorders can affect heart rhythm, blood pressure, hydration, electrolytes, liver function, and nutritional status. Those factors can change the risk profile of any treatment that affects blood pressure, consciousness, nausea, or metabolism. A clinician should assess current medical stability rather than relying on diagnosis alone.

For anorexia nervosa, very low weight, dehydration, electrolyte abnormalities, fainting, chest symptoms, or significant cardiovascular concerns may require stabilization and specialist care before an elective ketamine discussion. For bulimia nervosa, vomiting and laxative use can contribute to electrolyte changes that deserve prompt medical attention. For binge-eating disorder, co-occurring depression, anxiety, substance use, and medications may be more relevant to the individual risk assessment.

Dissociation, nausea, increased blood pressure, sedation, and perceptual changes are known ketamine-related concerns. Nausea may be especially difficult for someone with a history of purging or fear of vomiting. A medication and substance review also matters because interactions can alter safety or treatment planning. See common ketamine side effectsketamine drug interactions, and cardiovascular monitoring for related questions.

When a conversation about ketamine may be reasonable

A discussion may be reasonable when a person is already engaged in evidence-based eating disorder care, has a clear co-occurring condition such as treatment-resistant depression, and can receive coordinated medical and mental health follow-up. The goal should be defined in advance. For example, the goal may be to reduce severe depressive symptoms enough to participate more consistently in therapy, not to treat eating disorder symptoms with ketamine alone.

It may be a poor fit when there is acute medical instability, uncontrolled blood pressure concerns, active intoxication, an inability to arrange follow-up, or a treatment plan that would displace nutrition and psychotherapy. Individual contraindications and risks require clinician judgment.

Questions to bring to a clinician

Use these questions to make the decision concrete and keep care coordinated.

Keep established treatment at the center

Specialized psychotherapy, nutritional rehabilitation when indicated, medical monitoring, and support for co-occurring conditions remain the foundation of care. The National Institute for Health and Care Excellence describes psychological treatment and physical health monitoring as central parts of eating disorder treatment. Its recommendations are available in the NICE eating disorders guideline.

If ketamine is considered, integration and follow-up should support the existing treatment plan. A structured session after treatment may help a patient and therapist discuss mood changes, distressing effects, and how to apply any increased flexibility to therapy goals. Learn more about ketamine integration therapy.

Bottom line

Low dose ketamine for eating disorders is an emerging clinical question, not a proven stand-alone intervention. The safest next step is an individualized conversation with an eating disorder specialist and the clinician considering ketamine, with medical stability and continuity of care treated as non-negotiable parts of the decision.